Impact of a Medication Review on Hospital Readmission: (ConcReHosp)

Re-hospitalization Clinical Trial

— ConcReHosp  

Official title:

Impact of a Medication Review on Hospital Readmission: Study Protocol of a Randomized Controlled Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02734017
• Other study ID #: 2015-20
• Status: Terminated
• Phase: N/A
• Start date: July 1, 2016
• Est. completion date: March 23, 2019

Study information

• Verified date: July 2023
• Source: Assistance Publique Hopitaux De Marseille
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is a randomized controlled clinical trial. A total 1400 hospitalized patients will be randomized in two groups:

1. group receiving a pharmacist-led standardized medication review (experimental group); and

2. group not receiving the medication review (control group).

The patients will be followed up at 30 days after initial hospitalization. Outcome measures include the number of readmissions; patient satisfaction, quality of medical admission prescription and number of consultation after initial hospitalization.

Discussion: A randomized controlled trial will provide the highest level of evidence on the impact of pharmacist-led standardized medication review on early hospital readmission for extreme age population.

Description:

The impact of Medication Reconciliation on the early hospital readmission in the elderly is not clearly demonstrated. Moreover, the impact of medication reconciliation in the pediatric population is poorly studied.

In such context, it is important to demonstrate the effectiveness of the medication reconciliation as part of a standardized medication review process, in pediatric and in the elderly, on all cause readmissions in a large randomized control clinical trial. The standardized medication review process includes medication reconciliation, treatment review and medication liaison service.

The main objective of this study is to assess the impact of the standardized medication review on the rate of readmissions and/or death at 30 days following initial hospitalization discharge.

Methods/design: The study is a randomized controlled clinical trial. A total 1400 hospitalized patients will be randomized in two groups:

1. group receiving a pharmacist-led standardized medication review (experimental group); and

2. group not receiving the medication review (control group).

The patients will be followed up at 30 days after initial hospitalization. Outcome measures include the number of readmissions; patient satisfaction, quality of medical admission prescription and number of consultation after initial hospitalization.

Discussion: A randomized controlled trial will provide the highest level of evidence on the impact of pharmacist-led standardized medication review.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 470
• Est. completion date: March 23, 2019
• Est. primary completion date: January 2, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Subjects aged under 18 or over 65 years

• Subject hospitalized in the multidisciplinary pediatric service or internal medicine ward, after emergency department visit at Timone hospital (Marseille, France) regardless of the reason for admission

• Subject with or without any comorbidity

• Living in France

• With national publicly-founded health insurance

Inclusion criteria for parents of minor child:

• Major subject and/or holder of parental authority of a hospitalized child, who fulfills the eligibility criteria mentioned above, in the multidisciplinary pediatric ward;

• Whatever the reason for hospitalization of the patient;

Inclusion criteria for the caregivers of patients older than 65 years:

• Major subject, designated by the patient or designating himself as the person most involved in the daily life of the patient;

• Whatever the reason for hospitalization of the patient;

• Whatever relationship or proximity to the study patient (family member, friend, neighbor);

Exclusion Criteria:

• Patients whose care requires regular re-hospitalization / programmed less than 30 days after discharge of initial hospitalization

• Vulnerable persons according to French law (pregnant women, adults under guardianship, persons deprived of liberty)

Related Conditions & MeSH terms

• Re-hospitalization

Intervention

Other:
• pharmacist-led standardized medication review
the goal of this study is to assess the impact of the standardized medication review on the rate of readmissions and/or death at 30 days following initial hospitalization discharge.

Locations

Country	Name	City	State
France	Hôpital de la Timone Assistance Publique Hôpitaux de Marseille	Marseille

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique Hopitaux De Marseille

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of readmission		30 days
Secondary	Satisfaction with Medicines Questionnaire (SatMed-Q®)	Patient satisfaction with regards to its drug treatment will be measured using the standardized questionnaire "Satisfaction with Medicines Questionnaire (SatMed-Q®)" validated in French	30 days
Secondary	Medication errors on medical admission prescription	Medical admission prescription will be assessed using the number of discrepancies and the number of medication errors,	24 hours
Secondary	Number of consultations post discharge	The number of consultations scheduled or not within 30 days' post-hospitalization will be studied. Consultations are defined as interviews with the attending physician, a specialist physician, nurse, therapeutic educator, and psychologist.	30 days